12:00 AM
 | 
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

NEOD001 regulatory update

EMA granted Orphan Drug designation to Prothena's NEOD001 to treat amyloid light-chain amyloidosis. Early this...

Read the full 55 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >